Using this data, Everist created the world’s only molecular diagnostic test, OncoDefender-CRC, which can accurately identify tumors at high risk for recurrence among early-stage colon and rectal cancers. The test became commercially available in November, and the company has received physician requests for more than 1,000 specimen collection kits. Sanford Health Plan, which provides insurance in South Dakota, North Dakota, Iowa, Minnesota and Nebraska, has established a policy that will reimburse members for the test beginning in Jan. 2012.
Related Articles on Colorectal Cancer Screening:
Water Infusion for Cecal Intubation Increases Patient Tolerance, but not Intubation in Unsedated Colonoscopy
AGA Releases New Standards for Performing CT Colonography
Colonoscopy Best for Monitoring Mucosal Healing in Patients With Ulcerative Colitis
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
